Nazanin Mirzaei

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5149795/publications.pdf

Version: 2024-02-01

		840776	1125743	
15	712	11	13	
papers	citations	h-index	g-index	
16	16	16	1338	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Imidazoline ligand BU224 reverses cognitive deficits, reduces microgliosis and enhances synaptic connectivity in a mouse model of Alzheimer's disease. British Journal of Pharmacology, 2021, 178, 654-671.	5.4	11
2	Retinal Vasculopathy in Alzheimer's Disease. Frontiers in Neuroscience, 2021, 15, 731614.	2.8	40
3	Astrocyte Reactivity in Alzheimer's Disease: Therapeutic Opportunities to Promote Repair. Current Alzheimer Research, 2021, 18, .	1.4	6
4	Retina mirrors brain pathology and response to GA immunotherapy in advanced stage AD-model mice Alzheimer's and Dementia, 2021, 17 Suppl 3, e055329.	0.8	0
5	Retinal vascular abnormalities and blood-retinal barrier breakdown in Alzheimer's disease Alzheimer's and Dementia, 2021, 17 Suppl 3, e056603.	0.8	0
6	Ablation of reactive astrocytes exacerbates disease pathology in a model of Alzheimer's disease. Glia, 2020, 68, 1017-1030.	4.9	53
7	Parallels between retinal and brain pathology and response to immunotherapy in old, lateâ€stage Alzheimer's disease mouse models. Aging Cell, 2020, 19, e13246.	6.7	32
8	Alzheimer's Retinopathy: Seeing Disease in the Eyes. Frontiers in Neuroscience, 2020, 14, 921.	2.8	61
9	Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina. Acta Neuropathologica, 2020, 139, 813-836.	7.7	113
10	PPARγ-coactivator-1α gene transfer reduces neuronal loss and amyloid-β generation by reducing \hat{I}^2 -secretase in an Alzheimerâ \in ™s disease model. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12292-12297.	7.1	106
11	<i>In vivo</i> imaging of microglial activation by positron emission tomography with <scp>[¹¹C]PBR28</scp> in the <scp>5XFAD</scp> model of <scp>A</scp> zheimer's disease. Glia, 2016, 64, 993-1006.	4.9	71
12	Cascades and Cognitive State: Focused Attention Incurs Subcritical Dynamics. Journal of Neuroscience, 2015, 35, 4626-4634.	3.6	71
13	Systemic administration of fibroblast growth factor-2 (FGF2) reduces BACE1 expression and amyloid pathology in APP23 mice. Neurobiology of Aging, 2015, 36, 821-831.	3.1	42
14	Activation of the Wnt∫l²â€catenin pathway represses the transcription of the βâ€amyloid precursor protein cleaving enzyme (BACE1) via binding of Tâ€cell factorâ€4 to BACE1 promoter. FASEB Journal, 2015, 29, 623-635.	0.5	82
15	Dose-dependent Neuroprotection of VEGF165 in Huntington's Disease Striatum. Molecular Therapy, 2013, 21, 1862-1875.	8.2	24